. 2023 May 16;15:17588359231173183. doi: 10.1177/17588359231173183

Table 3.

Ongoing Phase III clinical trials investigating the combination of PARPi and immune checkpoint inhibitors.

Study name (NCT number)	Treatment setting	Patient population	Arms of study
ANITA (NCT03598270)¹³	Platinum-sensitive relapse	All comers	(A) Atezolizumab + chemo, followed by maintenance niraparib + placebo (B) Atezolizumab + chemo, followed by maintenance niraparib + atezolizumab
Keylynk-001 (NCT03740165)¹⁴	First-line maintenance	BRCA1/2 wt	(A) Bevacizumab + placebo + placebo (B) Bevacizumab + pembrolizumab + placebo C)Bevacizumab + pembrolizumab + olaparib
FIRST (NCT03602859)¹⁵	First-line maintenance	All comers	(A) Bevacizumab + placebo + placebo (B) Bevacizumab + niraparib + placebo (C) Bevacizumab + niraparib + dostarlimab
ATHENA (NCT03522246)¹⁶	First-line maintenance	All comers	(A) Placebo + placebo (B) Nivolumab + placebo (C) Placebo + rucaparib (D) Nivolumab + rucaparib
DUO-O (NCT03737643)¹⁷	First-line maintenance	All comers	(A) Bevacizumab + placebo + placebo (B) Bevacizumab + durvalumab + placebo (C)Bevacizumab + durvalumab + olaparib

BRCA1/2 wt, BRCA1/2 wild-type; PARPi, PARP inhibitors.